



Department of Obstetrics and Gynaecology
Queen Mary Hospital
The University of Hong Kong



Gynaecological Oncology

Annual Report
2021



Gynaecological Oncology

Department of Obstetrics and Gynaecology
Queen Mary Hospital
The University of Hong Kong

Annual Report 2021



**HKU
Med**

School of Clinical Medicine
Department of Obstetrics
& Gynaecology
香港大學婦產科學系

Message from Division Head

The gynaecological oncology division of the Department of Obstetrics and Gynaecology, the University of Hong Kong, has been providing training and service in gynaecological oncology for over 50 years. Our unit is a tertiary referral center for both the private and public sectors in Hong Kong. We also accept referrals from the hospitals in Macau. With collaboration with other departments, our scope of services includes colposcopy, chemotherapy, radiotherapy, surgery and palliative care.

Our unit is a recognized training center for gynaecological oncology by the Hong Kong College of Obstetricians and Gynaecologists (HKCOG) and the Royal College of Obstetricians and Gynaecologists (RCOG). Dr Kwok Shuk Tak started her first year subspecialist training in gynaecological oncology since January 2021. We had Dr. Li Xian with us for his last 6 months of joint The University of Hong Kong-ShenZhen hospital (HKU-SZH) Gynaecological Oncological Subspecialty training programme. Apart from training subspecialist fellow, we also provide gynaecological oncology training for basic and higher specialist trainees in Obstetrics and Gynaecology, not only from our unit but also other hospitals in Hong Kong.

In addition to clinical service and research activities, our division was also active in promoting women's health in Hong Kong by giving public talks and presentations in the Family Planning Association, radio and TV programmes.

I would like to take this opportunity to thank our team members and our collaborators for their contribution and maintain our service during the COVID pandemic.



Karen K.L. Chan
Department Chairperson

Table of contents

I	Staff List	4
II	Laboratory	7
III	Inpatient & Outpatient Services	9
IV	Team Activities	10
V	Outpatient Statistics	11
VI	Colposcopy Services	12
VII	Cervical Malignancies	14
VIII	Uterine Malignancies	15
IX	Ovarian Malignancies	17
X	Gestational Trophoblastic Neoplasia	19
XI	Vulval, Vaginal and Fallopian Tube Cancers	20
XII	Multiple Primary Malignancies	21
XIII	Operations for Malignant/Pre-malignant Diseases	22
XIV	Chemotherapy	25
XV	Publications and Abstracts	27

Staff List

Gynaecological Oncologists

Professor Ngan Yuen Sheung Hextan, Professor, Department of Obstetrics and Gynaecology, University of Hong Kong

Dr. Chan Kar Loen Karen, Associate Professor, Department of Obstetrics and Gynaecology, University of Hong Kong

Dr. Tse Ka Yu, Associate Professor, Department of Obstetrics and Gynaecology, University of Hong Kong

Dr. Chu Man Yee Mandy, Consultant, Department of Obstetrics and Gynaecology, Queen Mary Hospital

Dr. Ngu Siew Fei, Associate Professor, Department of Obstetrics and Gynaecology, University of Hong Kong

Subspecialist Trainee

Dr. Kwok Shuk Tak, Gladys, Resident Specialist, Department of Obstetrics and Gynaecology, Queen Mary Hospital

Specialist Gynaecologists

Dr. Li Xian, Resident Specialist, Department of Obstetrics and Gynaecology, HKU-SZH (1 Jan 2021 – 30 Jun 2021)

Dr Wong Keedon, Resident Specialist, Department of Obstetrics and Gynaecology, Queen Mary Hospital (1 Jul – 31 Dec 2021)

Residents

Dr. Lai Kit Yan, Francesca, Resident, Department of Obstetrics and Gynaecology, Queen Mary Hospital (1 Jan – 31 Mar 2021)

Dr. Chan Tsoi Yan, Dorothy, Resident, Department of Obstetrics and Gynaecology, Queen Mary Hospital (16 May – 30 June 2021)

Dr. Ho King Dat Stanton, Resident, Department of Obstetrics and Gynaecology, Queen Mary Hospital (1 Oct – 31 Dec 2021)

Clinical Oncologists

Dr. Yuen Kwok Keung, Chief of Service, Department of Clinical Oncology, Queen Mary Hospital

Dr. Siu Wai Kwan Steven, Consultant, Department of Clinical Oncology, Queen Mary Hospital

Pathologists

Professor Leung Suet-yi, Head of Department, Department of Pathology, University of Hong Kong

Professor Cheung Nga Yin Annie, Professor, Department of Pathology, University of Hong Kong

Dr. Ip Pun Ching Philip, Associate Professor, Department of Pathology, Queen Mary Hospital

Consultant Colorectal Surgeon

Professor Law Wai Lun, Professor, Department of Surgery, Queen Mary Hospital

Dr. Oswens Siu-Hung Lo, Consultant, Department of Surgery, Queen Mary Hospital

Consultant Urologist

Dr. Tsu Hok Leung James, Consultant & Division Chief, Department of Surgery, Queen Mary Hospital

Consultant Plastic Surgeon

Dr. Chow Ling Yu Velda, Consultant & Division Chief, Department of Surgery, Queen Mary Hospital

Consultant Medical Oncologist

Professor Kwong Yok Lam, Division of Haematology, Medical Oncology and Bone Marrow Transplantation, Department of Medicine, University of Hong Kong

Consultant Radiologist

Dr. Lam Poy Wing Tina, Chief of Service, Department of Radiology, Queen Mary Hospital

Dr. Lee Yuen Phin Elaine, Assistant Professor, Department of Radiology, University of Hong Kong

Consultant Anaesthesiologist

Dr. Chee Yee Eot, Chief of Service, Department of Anaesthesiology, Queen Mary Hospital

Consultant Clinical Psychologist

Dr. Lina Wu, Senior Clinical Psychologist, Department of Psychiatry, Queen Mary Hospital

Medical Social Workers

Ms Au Suk Cheung Helen, Social Welfare Department

Nurse Specialist in Stoma Care

Ms. Chan Lai Hung, Nursing Officer, Queen Mary Hospital

Oncology Case manager:

Ms. Wong Yan Yan, Priscilla, Advanced Practice Nurse, Queen Mary Hospital

Cluster Rehabilitative Palliative Care Team

Dr. Chan Kwok Ying, Consultant, Palliative Medicine Unit, Grantham Hospital

Dr. Li Cho Wing Bryan, Associate Consultant, Palliative Medicine Unit, Grantham Hospital

Ms. Chiu Ho Yan, Registered Nurse, Grantham Hospital

Clinical Research Team

Ms Lau Suk Kwan Lesley, Research Co-ordinator

Dr. Wei Na Tina, Research Co-ordinator

Laboratory

Staff

Dr. Chan Wai Sun, Post-doctoral Fellow
Dr. Yung Ming Ho Mingo, Post-doctoral Fellow
Dr. Liu Si Stephanie, Research Officer
Dr. Siu Kwan Yee Michelle, Research Officer
Mr. Kwok Ka Leung, Senior Technical Officer
Miss Hui Man Ning Lynn, Research Assistant

Services

Hormonal assay and assays for tumour markers

Research tools

HPV detection and genotyping
ELISA
Immunohistochemistry
In situ hybridization assay
DNA, RNA and protein extractions
Conventional PCR and RT-PCR
Quantitative PCR
Quantitative RT-PCR
RNA protection assay
Western blot
DNA methylation analysis
DNA sequencing
Microarray analysis
Hypoxia chamber
Flow cytometry
Yeast two hybrid
Fluorescent microscopy
Fluorescent stereomicroscopy
Li-Cor Odyssey CLx near-infrared fluorescence imaging system
Gel documentation system
Microplate reader
SpectraMax L Microplate Reader
Cell line and culture
Transfection study
RNAi study
CRISPR/Cas9 Gene Editing Clonogenic assay
Cytotoxicity assay
Cell proliferation assay
DNA copy number variation analysis
Protein co-immunoprecipitation
Gene cloning
In vivo animal study
Laser-captured microdissection
3D organoids assay
Omics analysis
Omental conditioned medium model
Ex vivo omental-tumor model

Inpatient Services

Gynaecological oncology ward

22 beds in the open ward
2 private beds
3 day beds

Ward Manager

Ms. Ho Pui Yee, Polly

Operating Theatre

2 Full-day lists per week

Operating Theatre DOM

Ms. Sylvia Wong

Outpatient Services

Colposcopy Clinic	4 sessions per week
Chemotherapy Clinic	1 session per week
Cancer follow-up Clinic	1 session per week
Trophoblastic Clinic	1 session per week
Day Chemotherapy	5 days per week
Patient Group Meeting	withheld due to COVID
Palliative Medicine Clinic	1 session per week
Pre-admission Clinic	1 session per week

Clinic In-charge

Ms. Chung Suk Man, Advanced Practice Nurse, S5, Queen Mary Hospital

Team Activities

Grand Round (Led by Dr Karen K.L. Chan)	1 per week
Discussion of New Cases and Treatment (Led by Dr Karen K.L. Chan)	1 per week
Radiology Meeting (Led by Dr Karen K.L. Chan and Dr. Elaine Lee)	1 per week
Chemotherapy Meeting (Led by Dr Karen K.L. Chan)	1 per week
Morbidities and Mortality Meeting (Led by Dr Karen K.L. Chan)	1 per week
Pre-operative Round (Led by Dr Karen K.L. Chan)	1 per week
Tumour Board Meeting/Pathology Review (Led by Dr Karen K.L. Chan and Prof. Annie Cheung)	1 per week
Laboratory Research Meeting (Led by Dr Karen K.L. Chan)	1 per month
Clinical Research Meeting (Led by Dr Karen K.L. Chan)	1 per 6 weeks

Outpatient Statistics

Oncology Clinics Attendances

	2017	2018	2019	2020	2021
Cancer Follow-up Clinic	4183	4322	4207	3918	3318
Trophoblastic Clinic	856	726	667	531	573
Chemotherapy Clinic	1758	2044	2219	2633	2577
Preadmission Clinic	-	95	174	162	139
Research Clinic			15	0	0

Patient Group Meeting

Oncology patients support group which was led by:

- Ms. Susanna Hui (Ward Manager)
- Ms. Tang Lai Chun (Advanced Practice Nurse)
- Ms. Cheng Sze Ki (Registered Nurse)

Stoma patients support group which was led by:

- Ms. Susanna Hui (Ward Manager)
- Ms. Chan Lai Hung (Nursing Officer)

Oncology patient support group: withheld due to COVID

Total no. of sessions: 0
 Total no. of attendance: 0

Stoma patient support group: withheld due to COVID

Total no. of sessions: 0
 Total no. of attendance: 0

Annual patient group party: withheld due to COVID

Colposcopy Services

Colposcopy Clinics

Queen Mary Hospital

4 sessions - Monday afternoon, Tuesday morning, Thursday and Friday afternoon

Statistics

New Cases	0
Follow-up	2


Diagnosis (based on worst histology)	Cervix	Vagina	Vulva
Normal	81	4	
Inflammation	29	1	
Warts/HPV	1	0	
Low grade squamous intraepithelial lesion	208	15	
High grade squamous intraepithelial lesion	60	4	
Microinvasive carcinoma	3		
Squamous cell carcinoma	3		
Adenocarcinoma	2		
Adenocarcinoma in-situ	2		
No histology	5	10	
Unsatisfactory for assessment	10		
Others	5		
Atrophy			
Atypical cells	2		
Endocervical polyp	2		
Gastric metaplasia	1		
Glandular dysplasia	1		

Procedures

Cone biopsy	3
Cryotherapy	3
Large loop excision of transformation zone	124
Under local anaesthesia	114
Under general / spinal anaesthesia	10


Cervical Malignancies

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
Total Number of New cases	62	83	84	82	87	101	73	84	91	63	77
Stage I	26	36	42	42	43	36	36	33	27	21	25
Stage II	27	22	21	19	17	26	18	24	23	10	15
Stage III	4	15	16	14	12	14	11	11	18	17	21
Stage IV	3	5	3	2	6	8	3	9	14	8	5
Unstaged	1	1	1	3	0	5	2	4	1	0	2
Recurrence	1	4	1	2	9	12	3	3	8	7	9



2021 New Case

Age	
≤ 30	2
31-40	17
41-50	20
51-60	16
61-70	13
71-80	7
> 80	2
Total	77




Uterine Malignancies

Carcinoma of Endometrium

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
Total Number of New Cases	78	110	121	146	115	134	128	147	162	149	155
Stage I	45	64	70	83	69	88	81	88	106	85	97
Stage II	5	10	8	16	10	10	11	14	9	8	6
Stage III	16	23	25	26	18	23	24	26	24	18	28
Stage IV	5	4	5	12	7	9	6	13	12	23	14
Unstaged	4	7	10	8	7	2	3	5	2	7	4
Recurrence	3	2	3	1	4	2	3	1	9	8	6

2021 New Case

Age	
≤ 30	1
31-40	15
41-50	25
51-60	51
61-70	41
71-80	17
> 80	5
Total	155



Other Uterine Malignancies


	2016	2017	2018	2019	2020	2021
Endometrial stromal sarcoma	5	3	8	3	4	6
Leiomyosarcoma	5	14	7	9	5	3
Malignant mixed mullerian tumor (MMMT)	8	11	8	8	8	11
Adenosarcoma	0	1	0	0	0	0
Chondrosarcoma	0	1	0	0	0	0
Rabdomyosarcoma	0	1	0	0	0	0
Smooth muscle tumour of undetermined malignant potential (STUMP)	3	0	1	3	2	1
Dedifferentiated endometrial carcinoma	0	1	0	0	0	0
Undifferentiated endometrial sarcoma	0	0	0	1	0	0
Uterine tumour resembling ovarian sex cord tumour	0	1	0	0	0	1

Uterine small cell carcinoma	1	0	1	0	0	0
Undifferentiated carcinoma	1	1	4	0	0	1
sarcoma					2	2
carcinosarcoma					1	0
neuroendocrine						1

Ovarian Malignancies


Epithelial Ovarian Cancer

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
Total Number of New cases	55	61	64	78	76	76	66	79	95	51	83
Stage I	22	26	30	25	22	32	14	27	40	23	25
Stage II	6	9	7	7	5	4	11	2	8	3	5
Stage III	21	16	16	32	33	16	22	14	25	12	23
Stage IV	6	4	10	9	10	13	12	14	15	8	13
Unstaged	0	2	1	1	1	2	1	1	0	0	0
Recurrence	0	4	0	4	5	9	6	21	7	5	17



2021 New Case

Age	
≤ 30	4
31-40	11
41-50	29
51-60	20
61-70	12
71-80	5
> 80	2
Total	83



Ovarian Tumour of Low Malignant Potential

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
Number of new cases	8	19	19	19	18	13	22	12	13	22	21
Stage I	7	15	14	15	16	6	19	10	12	20	17
Stage II	0	0	2	1	0	1	2	0	0	0	1
Stage III	0	2	2	2	2	1	0	1	1	1	1
Unstaged	0	0	1	0	0	0	0	0	0	1	0
Recurrence	1	2	0	1	0	4	1	0	0	0	2

Germ Cell Tumour

1 patient had stage at least 1a immature teratoma.

1 patient had stage 1c immature teratoma.

1 patient had 1c germ cell tumour.

Sex Cord-Stromal Tumour

3 patients had stage 1a granulosa cell tumour.

1 patient had stage 3a granulosa cell tumour.

Other Ovarian Malignancies

1 patient had stage 2b carcinosarcoma.

1 patient had unstaged extrauterine HGESS.

1 patient had unstaged papillary thyroid carcinoma arising from struma ovarii.

1 patient had mature teratoma with papillary thyroid carcinoma.


1 patient had recurrent extra-ovarian tumour of wolffian origin.

Primary Peritoneal Carcinoma

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
Total	3	13	10	10	9	15	9	11	16	10	9
Stage II	0	2	0	0	0	1	0	0	0	1	0
Stage III	1	5	7	4	7	9	1	6	8	4	2
Stage IV	2	5	3	4	1	4	3	4	7	4	5
Unstaged	0	1	0	1	0	1	4	1	1	1	0
Recurrence	0	0	0	1	1	0	1	0	0	0	2


Gestational Trophoblastic Neoplasia

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
Number of New cases	10	21	16	17	14	12	10	12	10	10	11
Stage I	9	18	12	10	8	8	8	9	6	8	10
Stage II	1	0	0	1	0	0	0	1	0	0	0
Stage III	0	2	2	5	2	2	2	2	2	2	1
Stage IV	0	1	2	0	1	1	0	0	1	0	0
Unstaged	0	0	0	0	0	0	0	0	1	0	0
Recurrence	0	0	0	1	1	1	0	0	0	0	0



2021 New case

Age	Case Number
≤ 30	1
31-40	3
41-50	6
> 50	1
Total	11



Vulval, Vaginal and Fallopian Tube Cancers

Vulval Cancer

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
Number of New Cases	5	8	7	9	6	6	9	12	1	13	4
Stage I	0	2	4	4	0	3	6	2	0	3	0
Stage II	0	1	0	0	1	0	0	4	0	0	0
Stage III	2	1	1	3	1	1	3	1	0	4	2
Stage IV	1	2	1	0	1	0	0	1	1	2	1
Unstaged	2	1	0	1	1	1	0	2	0	3	1
Recurrence	0	1	1	1	2	1	0	2	0	1	0

Vaginal Cancer

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
Number of New Cases	5	8	3	3	5	7	5	5	4	6	10
Stage I	0	2	0	1	0	0	0	0	0	0	4
Stage II	4	1	1	1	4	5	1	3	2	3	4
Stage III	1	1	0	0	0	0	1	2	0	0	1
Stage IV	0	2	2	0	1	1	2	0	0	3	0
Unstaged	0	1	0	0	0	0	0	0	1	0	0
Recurrence	0	1	0	1	0	1	1	0	1	0	1

Fallopian Tube Cancer

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
Number of New Cases	0	1	0	3	2	5	4	2	1	7	5
Stage I	0	1	0	0	0	0	1	0	0	1	0
Stage II	0	0	0	0	0	1	2	0	0	1	1
Stage III	0	0	0	1	0	2	0	1	1	2	4
Stage IV	0	0	0	2	2	1	1	0	0	2	0
Unstaged	0	0	0	0	0	0	0	0	0	0	0
Recurrence	0	0	0	0	0	1	0	1	0	1	0

Multiple Primary Malignancies

2021 Number
9

Primary	Stage	Primary	Stage	Number
Ca Corpus	1 +	Ca Ovary	1	2
Ca Corpus	1 +	Ca Ovary	3	1
Ca Corpus	1 +	Ca Fallopian Tube	2	1
Ca Corpus	2 +	Ca Ovary	1	1
Ca Corpus	2 +	Ca Sigmoid	3	1
Ca Corpus	2 +	Borderline Ovary		1
Ca Corpus	1 +	Ca Ovary	1	1

2 patients had Ca Corpus stage 1 and bilateral Ca Ovary stage 1.

Operation for Malignant/Pre-malignant Diseases

	Number of procedures
Laparotomy (all cases with open abdominal surgery)	124
Radical hysterectomy +/- unilateral / bilateral salpingo-oophorectomy (U/BSO)	9
Laparoscopic radical hysterectomy +/- U/BSO	0
Laparoscopic radical hysterectomy +/- U/BSO (Da Vinci)	2
Modified radical hysterectomy +/- U/BSO	6
Laparoscopic modified radical hysterectomy +/- U/BSO (Da Vinci)	1
Total abdominal hysterectomy +/- U/BSO	82
Total laparoscopic hysterectomy +/- U/BSO	43
Total laparoscopic hysterectomy +/- U/BSO (Da Vinci)	39
Laparoscopic radical trachelectomy	0
Laparoscopic radical trachelectomy (Da Vinci)	0
Pelvic lymphadenectomy (one side)	47 (3)
Laparoscopic pelvic lymphadenectomy (one side)	3 (1)
Laparoscopic pelvic lymphadenectomy (one side) (Da Vinci)	37
Paraaortic lymphadenectomy	35
Laparoscopic paraaortic lymphadenectomy	1
Laparoscopic paraaortic lymphadenectomy (Da Vinci)	29
Omentectomy	49
Laparoscopic omentectomy	7
Laparoscopic omentectomy (Da Vinci)	13
Adhesiolysis	21
Laparoscopic adhesiolysis	12
Laparoscopic adhesiolysis (Da Vinci)	4
BSO / USO / ovarian cystectomy	7

Laparoscopic BSO / USO / ovarian cystectomy	5
Laparoscopic BSO / USO / ovarian cystectomy (Da Vinci)	0
Appendicectomy	10
Laparoscopic appendicectomy	1
Laparoscopic appendicectomy (Da Vinci)	0
Debulking surgery	29
HIPEC	6
Bowel resection and re-anastomosis	2
Colostomy / ileostomy	3
Closure of stoma	0
Repair of bowel	0
Repair of bladder	0
Repair of vessels	0
Repair of vagina / perineum	0
Vault stripping / vaginectomy	6
Wide local excision of vulva	8
Radical vulvectomy	0
Groin node dissection (one side)	4
Cone biopsy	0
Large loop excision of transformation zone	2
Brachytherapy	12
Removal or insertion of central line insertion	0
Diagnostic hysteroscopy	11
Hysteroscopic polypectomy	0
Suction evacuation	1
Laparoscopic biopsy	16
Diagnostic laparoscopy	17
Examination under anaesthesia	0

Cystoscopy	2
Staging laparotomy	0
Lap myomectomy	0
Lap myomectomy (Da Vinci)	0
Biopsy of sentinel LN (Da Vinci)	1
Lap sentinel LN biopsy	11
Dilatation and curettage	0
Resection of fibroid	0
Biopsy of cervix	0
Local skin flap	0
Resuturing of post-operative abdominal wound	0
Colposcopy, Cervical biopsy, endocervical curettage, Diagnostic hysteroscopy, curettage	6
Diaphragm stripping	4
Total exenteration	1
Lap assisted vaginal total hysterectomy (vNOTES)	9

Chemotherapy

Total number of patients receiving in-patient chemotherapy: 229

Total number of patients receiving out-patient chemotherapy: 301

Total number of patients receiving oral chemotherapy: 15

Total number of patients receiving PARP inhibitors: 52

Chemotherapy Regimen	Number of courses	
	In patient	Outpatient
Actinomycin D	0	1
Adriamycin	11	36
Avelumab/Axitinib (clinical trial)	23	36
axitinib (oral)	0	6
BEP (bleomycin, etoposide, cisplatin)	6	5
Bevacizumab	11	45
Carboplatin	5	24
Carboplatin (weekly) /Paclitaxel (weekly)	5	2
Carboplatin/Etoposide	3	3
Carboplatin/Gemcitabine	16	48
Carboplatin/Gemcitabine/Bevacizumab	11	11
Carboplatin/Liposomal doxorubicin	2	23
Carboplatin/Paclitaxel	243	556
Carboplatin/Paclitaxel (weekly)	0	2
Carboplatin/Paclitaxel/Bevacizumab	18	39
Carboplatin/Paclitaxel/Durvalumab/Placebo	26	3
Carboplatin/Taxotere/Bevacizumab	5	1
Cisplatin	6	85
Cisplatin/Gemcitabine	11	14
Cisplatin/Paclitaxel	2	0
Cyclophosphamide (oral)	0	31
Durvalumab/Placebo	2	5
Durvalumab/Placebo+Olaparib/Placebo	0	4
EMA-CO (etoposide, methotrexate and actinomycin D/ cyclophosphamide and vincristine)	14	0
Gemcitabine	19	54
Gemcitabine/Paclitaxel	0	2
Gemcitabine/Taxotere	3	8
Ifosfamide	8	0

Liposomal doxorubicin	14	43
Liposomal doxorubicin/Bevacizumab	0	10
Melphalan	0	2
Methotrexate (intravenous)	39	0
Methotrexate/Actinomycin D	25	0
Niraparib	0	255
Olaparib	0	190
Paclitaxel	24	58
Paclitaxel, cisplatin/Paclitaxel, etoposide	0	3
Paclitaxel/Bevacizumab	2	0
Pembrolizumab	4	21
Pembrolizumab/Lenvatinib	9	18
Taxotere	1	4
Topotecan	30	68
Topotecan/Bevacizumab	4	5
Trametinib (oral)	0	14
XELOX (capecitabine and oxaliplatin)	1	5
Total number of courses of chemotherapy	603	1740

Publication

Scholarly books, monographs and chapters

El Helali A., Kwok S.T.G. and Tse K.Y., [Adjuvant and post-surgical treatment in non-epithelial ovarian cancer](#), Best Practice & Research Clinical Obstetrics & Gynaecology. 2021, 78, 74-85. (Publication No. : 334098; Weighting : 0.6667; Publication Date: Aug 2021)

Journal publications

Chan D.W., Lam W.Y., Chen F., Yung M.H., Chan Y.S., Chan W.S., He F., Liu S., Chan K.K.L., Li B. and Ngan H.Y.S., [Genome-wide DNA methylome analysis identifies methylation signatures associated with survival and drug resistance of ovarian cancers](#), Clinical Epigenetics. 2021, 13. <http://dx.doi.org/10.1186/s13148-021-01130-5> (Publication No. : 325608; Weighting : 0.8182; Publication Date: Dec 2021)

Chan K.K.L., Siu K.Y., JIANG Y., WANG J., WANG Y., Leung T.H.Y., Cheung A.N.Y. and Ngan H.Y.S., Differential expression of estrogen receptor subtypes and variants in ovarian cancer: effects on cell invasion, proliferation and prognosis, BMC Cancer. <http://dx.doi.org/10.1186/s12885-017-3601-1> (Publication No. : 277055; Weighting : 0.7500; Date Accepted for Publication: Aug 2017)

Chan K.K.L., Yeung C.K., Lam K.W., Cheung J.L.K., Sreedhar B. and Ngan H.Y.S., [Robotic Natural Orifice Transluminal Endoscopic Surgery Hysterectomy and Salpingo-Oophorectomy in a Porcine Model](#), Surgical Innovation. 2021, 155335062110184. <http://dx.doi.org/10.1177/15533506211018433> (Publication No. : 327495; Weighting : 0.3333; Publication Date: May 2021)

Chen W.C., Ngan H.Y.S., Yang L.Y., Chang W.Y., Wu R.C., Chen C.Y., Lin H., Cheng Y.M., Kan Y.Y., Tseng C.J., Chang C.C., Jung S.M., Tung H.J., Tang Y.H., Lin C.T., Chao A. and Lai C.H., [Verification of HPV16 as a good prognostic factor for cervical adenocarcinoma via an international collaborative study](#), Taiwanese Journal of Obstetrics and Gynecology. 2022, 61, 494-500. <http://dx.doi.org/10.1016/j.tjog.2022.03.036> (Publication No. : 333238; Weighting : 0.0588; Publication Date: May 2022)

El Helali A., Wong H.L.C., Choi C.W., Chan W.L.W., Dickson N., Siu W.K.S., Chan K.K.L., Ngan H.Y.S., Ngan K.C.R. and Kennedy R.D., [A comprehensive systematic review and network meta-analysis: the role of anti-angiogenic agents in advanced epithelial ovarian cancer](#), Scientific Reports. 2022, 12. <http://dx.doi.org/10.1038/s41598-022-07731-1> (Publication No. : 333241; Weighting : 0.2000; Publication Date: Dec 2022)

Fan S.L., Choi P.H., Ko W.T., Kwok Y.Y., Wong J.Y.H., Fong D.Y.T., Shek W.M.N., Ngan H.Y.S., Li J., H Y.Y., O Y.Q. and Lok Y.W.K., [Covid-19 Related Fear And Depression Of Pregnant Women And New Mothers](https://doi.org/10.1111/phn.13035), Public Health Nursing. 2021. <http://dx.doi.org/10.1111/phn.13035> (Publication No. : 331236; Weighting : 0.1667; Publication Date: Dec 2021)

HE J., Siu K.Y., Ngan H.Y.S. and Chan K.K.L., [Aberrant Cholesterol Metabolism in Ovarian Cancer: Identification of Novel Therapeutic Targets](https://doi.org/10.3389/fonc.2021.738177), Frontiers in Oncology. 2021, 11. <http://dx.doi.org/10.3389/fonc.2021.738177> (Publication No. : 333418; Weighting : 1.0000; Publication Date: Nov 2021)

Han C., Patten D., Kim S., Lim J., Chan D.W., Siu K.Y., Han Y., Carmona E., Parks R., Lee C., Di L.J., Lu Z., Chan K.K.L., Ku J.L., Macdonald E., Vanderhyden B., Mes-Masson A.M., Ngan H.Y.S., Cheung A.N.Y., Song Y., Bast R., Harper M.E. and Tsang B., [Nuclear HKII-P-p53 \(Ser15\) Interaction is a Prognostic Biomarker for Chemosensitiveness and Glycolytic Regulation in Epithelial Ovarian Cancer](https://doi.org/10.3390/cancers13143399), Cancers. 2021, 13, 3399. <http://dx.doi.org/10.3390/cancers13143399> (Publication No. : 327493; Weighting : 0.1739; Publication Date: Jul 2021)

JIANG Y., Siu K.Y., WANG J., Leung T.H.Y., Chan D.W., Cheung A.N.Y., Ngan H.Y.S. and Chan K.K.L., [PFKFB3 Regulates Chemoresistance, Metastasis and Stemness via IAP Proteins and the NF- \$\kappa\$ B Signaling Pathway in Ovarian Cancer](https://doi.org/10.3389/fonc.2022.748403), Frontiers in Oncology. 2022, 12. <http://dx.doi.org/10.3389/fonc.2022.748403> (Publication No. : 333243; Weighting : 0.8750; Publication Date: Jan 2022)

Klinosky D.J., Ho W.L., Ho S.L., Leung C.T.G., Liu H., Pang S.Y.Y., Ramsden D.B., Chan D.W. and Chan Y.S., Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition), Autophagy. 2021, 17(1), 1-382. (Publication No. : 330237; Weighting : 0.1111; Publication Date: Jan 2021)

Kwok A.L., Wong G.W., Wong E.S.Y., Tsun O.K.L., Chan K.K.L. and Cheung A.N.Y., Caution over use of ES2 as a model of ovarian clear cell carcinoma , Journal of Clinical Pathology. [http://dx.doi.org/10.1136/jclinpath-2014-202430](https://doi.org/10.1136/jclinpath-2014-202430) (Publication No. : 232390; Weighting : 0.1667; Date Accepted for Publication: Jul 2014)

Kwong A., Shin V.Y., Ho Y.S.C., Khalid A., Au C.H., Chan K.K.L., Ngan H.Y.S., Chan T.L. and Ma E.S.K., [Germline PALB2 mutation in high-risk Chinese breast and/or ovarian cancer patients](https://doi.org/10.3390/cancers13164195), Cancers. 2021, Epub on 2021-08-20. <http://dx.doi.org/10.3390/cancers13164195> (Publication No. : 325084; Weighting : 0.2222; Publication Date: Aug 2021)

Kwong A., Ho C.Y.S., Shin V.Y., Au C.H., Luk W.P., Fung L.H., Chan T.L., Chan K.K.L., Ngan H.Y.S. and Ma E.S.K., [Germline mutations in Chinese ovarian cancer with or without breast cancer](https://doi.org/10.1002/mgg3.1940), Molecular Genetics & Genomic Medicine. 2022. <http://dx.doi.org/10.1002/mgg3.1940> (Publication No. : 333341; Weighting :

0.2000; Publication Date: May 2022)

LIANG R., Yung M.H., He F., JIAO P., Chan K.K.L., Ngan H.Y.S. and Chan D.W., [The Stress-Inducible BCL2A1 Is Required for Ovarian Cancer Metastatic Progression in the Peritoneal Microenvironment](https://doi.org/10.3390/cancers13184577), *Cancers*. 2021, 13, 4577. <http://dx.doi.org/10.3390/cancers13184577> (Publication No. : 325611; Weighting : 1.0000; Publication Date: Sep 2021)

Li J., Wu R., Yung M.H., Sun J., Li Z., Yang H., Zhang Y., Liu S., Cheung A.N.Y., Ngan H.Y.S., Braisted J.C., Zheng W., Wei H., Gao Y., Nemes P., Pei H., Chan D.W., Li Y. and Zhu W., [SENP1-mediated deSUMOylation of JAK2 regulates its kinase activity and platinum drug resistance](https://doi.org/10.1038/s41419-021-03635-6), *Cell Death & Disease*. 2021, 12. <http://dx.doi.org/10.1038/s41419-021-03635-6> (Publication No. : 322766; Weighting : 0.2105; Publication Date: Apr 2021)

Liu S., Chan K.K.L., Chu K.H., Wei N., Lau S.K., Ngu S.F., Chu M.Y.M., Tse K.Y., Ip P.C.P., Ng K.O., Cheung A.N.Y. and Ngan H.Y.S., Oncogenic microRNA signature for early diagnosis of cervical intraepithelial neoplasia and cancer, *Molecular Oncology*. (Publication No. : 291315; Weighting : 0.7500; Date Accepted for Publication: Sep 2018)

Lok J., Tse K.Y., Lee E.Y.P., Wong R.W.C., Cheung I.S.Y., Chan A.N.H., Leung C.K.L., Cheung A.N.Y. and Ip P.C.P., [Intraoperative Frozen Section Biopsy of Uterine Smooth Muscle Tumors](https://doi.org/10.1097/PAS.0000000000001746), *American Journal of Surgical Pathology*. Wolters Kluwer Health, 2021, 45, 1179-1189. <http://dx.doi.org/10.1097/PAS.0000000000001746> (Publication No. : 323360; Weighting : 0.1111; Publication Date: Jun 2021)

Lok Y.W.K., Ko W.T., Fan S.L., Wong J.Y.H., Choi P.H., Shek W.M.N., Ngan H.Y.S., Tarrant A.M., Li J., Huang Y.Y., Ouyang Y.Q. and Fong D.Y.T., [International survey on fear and childbirth experience in pregnancy and the postpartum period during the COVID-19 pandemic: study protocol](https://doi.org/10.1136/bmjopen-2021-050132), *BMJ Open*. 2021, 11, e050132. <http://dx.doi.org/10.1136/bmjopen-2021-050132> (Publication No. : 324154; Weighting : 0.1667; Publication Date: Aug 2021)

Lok Y.W.K., Fan S.L., Ko W.T., Kwok Y.Y., Wong J.Y.H., Fong D.Y.T., Shek W.M.N., Ngan H.Y.S. and Choi P.H., [Validating the use of the revised childbirth experience questionnaire in Hong Kong](https://doi.org/10.1186/s12884-022-04456-x), *BMC Pregnancy and Childbirth*. 2022, 22. <http://dx.doi.org/10.1186/s12884-022-04456-x> (Publication No. : 332059; Weighting : 0.2222; Publication Date: Feb 2022)

Moloney K., Janda M., Frumovitz M., Leitao M., Abu-Rustum N.R., Rossi E., Nicklin J.L., Plante M., Lecuru F.R., Buda A., Mariani A., Leung Y., Ferguson S.E., Pareja R., Kimmig R., Tong P.S.Y., McNally O., Chetty N., Liu K., Jaaback K., Lau C., Ng S.Y.J., Falconer H., Persson J., Land R., Martinelli F., Garrett A., Altman A., Pendlebury A., Cibula D., Altamirano R., Brennan D., Ind T.E., De Kroon C., Tse K.Y., Hanna G. and Obermair A., [Development of a surgical competency assessment tool for sentinel lymph node dissection by minimally invasive surgery for endometrial cancer](https://doi.org/10.1186/s12884-022-04456-x), *International Journal of Gynecologic*

Cancer. 2021, 31, 647-655. <http://dx.doi.org/10.1136/ijgc-2020-002315> (Publication No. : 324206; Weighting : 0.0270; Publication Date: May 2021)

Ngan

H.Y.S., Seckl M.J., Berkowitz R.S., Xiang Y., Golfier F., Sekharan P.K., Lurain J.R. and Massuger L., [Diagnosis and management of gestational trophoblastic disease: 2021 update](#), International Journal of Gynecology & Obstetrics. 2021, 155, 86-93. <http://dx.doi.org/10.1002/ijgo.13877> (Publication No. : 333425; Weighting : 0.1250; Publication Date: Oct 2021)

Ng S.F., A patient with newly diagnosed Stage III clear cell BRCA-mutated ovarian cancer treated with more than 2 years of PARPi maintenance therapy, MIMS Oncology. 2021, July - August 2021, 20-21. (Publication No. : 324725; Weighting : 1.0000; Publication Date: Aug 2021)

Ng S.F., Ngan H.Y.S. and Chan K.K.L., A patient with relapsed high-grade serous ovarian carcinoma with somatic RAD51C mutations treated with PARPi monotherapy: A case report, Cancer Drug Resist. <http://dx.doi.org/10.20517/cdr.2022.12> (Publication No. : 333356; Weighting : 1.0000; Date Accepted for Publication: Apr 2022)

Ng S.F., Chai Y.K.V., Choi K.M.C., Leung T.W., Li J., Kwok S.T.G., Chu M.Y.M., Tse K.Y., Cheung V.Y.T., Ngan H.Y.S. and Chan K.K.L., Diagnostic Performance of Risk of Malignancy Algorithm (ROMA), Risk of Malignancy Index (RMI) and Expert Ultrasound Assessment in a Pelvic Mass Classified as Inconclusive by International Ovarian Tumour Analysis (IOTA) Simple Rules., Cancers (Basel). . 2022, 14(3), 810. <http://dx.doi.org/10.3390/cancers14030810> (Publication No. : 332030; Weighting : 0.9091; Publication Date: Feb 2022)

Ng S.F., Lau S.K., Li J., Wong C.Y.G., Cheung A.N.Y., Ngan H.Y.S. and Chan K.K.L., Human Papillomavirus Self-Sampling for Primary Cervical Cancer Screening in Under-Screened Women in Hong Kong during the COVID-19 Pandemic., Int J Environ Res Public Health.. 2022, 19(5), 2610. <http://dx.doi.org/10.3390/ijerph19052610> (Publication No. : 332269; Weighting : 0.7143; Publication Date: Feb 2022)

Ng S.F., Tse K.Y., Chu M.Y.M., Ngan H.Y.S. and Chan K.K.L., Olaparib dose re-escalation in ovarian cancer patients who experienced severe and/or uncommon adverse events: A case series., Asia Pac J Clin Oncol.. 2021, 17, 3-11. <http://dx.doi.org/10.1111/ajco.13584> (Publication No. : 322792; Weighting : 1.0000; Publication Date: Apr 2021)

Ng S.F., Ngan H.Y.S. and Chan K.K.L., [Role of adjuvant and post-surgical treatment in gynaecological cancer](#), Best Practice & Research Clinical Obstetrics & Gynaecology. 2021. <http://dx.doi.org/10.1016/j.bpobgyn.2021.09.001> (Publication No. : 327494; Weighting : 1.0000; Publication Date: Sep 2021)

Tsang T.H.F., Wong K.H., Allen K., Chan K.K.L., Chan M.C.M., Chao D.V.K., Cheung A.N.Y., Fan C.Y.M., Hui E.P., Ip

D.K.M., Lam

K.O., Lam C.K., Law W.L., Loong H.H.F., Wong K.H., Wong M.C.S., Yeung R.M. W., Ying A.C.H. and Ho R.K.W., [Update on the recommendations on breast cancer screening by the cancer expert working group on cancer prevention and screening](https://doi.org/10.12809/hkmj219622), *Hong Kong Medical Journal*. 2022, 28(2), 161-68. <http://dx.doi.org/10.12809/hkmj219622> (Publication No. : 332994; Weighting : 0.0526; Publication Date: Apr 2022)

Tse

K.Y., Domingo E.J., Konar H., Kumarasamy S., Pariyar J., Tjokroprawiro B.A., Ushijima K., Inthasorn P., Tan A.L. and Wilailak S., [COVID-19 and gynecological cancers: Asia and Oceania Federation of Obstetrics and Gynecology oncology committee opinion](https://doi.org/10.1111/jog.14579), *Journal of Obstetrics and Gynaecology Research*. 2021, 47, 1643-1650. <http://dx.doi.org/10.1111/jog.14579> (Publication No. : 324205; Weighting : 0.1000; Publication Date: May 2021)

Tse

K.Y., Wong R.W.C., Chao A., Ueng S.H., Yang L.Y., Cummings M., Smith D., Lai C .R., Lau H.Y., Yen M.S., Cheung A.N.Y., Leung C.K.L., Chan K.S., Chan A.N.H., Li W.H., Choi K.M.C., Pong W.M., Hui H.F., Yuk J.Y.W., Yao H., Yuen N.W.F., Obermair A., Lai C .H., Ip P.C.P. and Ngan H.Y.S., [Development of a Multi-Institutional Prediction Model for Three-Year Survival Status in Patients with Uterine Leiomyosarcoma \(AGOG11-022/QCGC1302 Study\)](https://doi.org/10.3390/cancers13102378), *Cancers*. 2021, 13, 2378. <http://dx.doi.org/10.3390/cancers13102378> (Publication No. : 324208; Weighting : 0.2000; Publication Date: May 2021)

Tse K.Y., Liu J., Lee S.J. and Tan D.S.P., [Editorial: Harnessing DNA Damage Response in Gynecologic Malignancies](https://doi.org/10.3389/fonc.2022.882925), *Frontiers in Oncology*. 2022, 12. <http://dx.doi.org/10.3389/fonc.2022.882925> (Publication No. : 333927; Weighting : 0.2500; Publication Date: Mar 2022)

WAN K.T., Leung T.H.Y., Siu K.Y., MO X., Tang W.M., Chan K.K.L., Cheung A.N.Y. and Ngan H.Y.S., [HPV-induced Nurr1 promotes cancer aggressiveness, self-renewal, and radioresistance via ERK and AKT signaling in cervical cancer](https://doi.org/10.1016/j.canlet.2020.09.025), *Cancer Letters*. 2021, 497, 14-27. <http://dx.doi.org/10.1016/j.canlet.2020.09.025> (Publication No. : 319247; Weighting : 0.8750; Publication Date: Jan 2021)

WANG H., Yung M.H., Ngan H.Y.S., Chan K.K.L. and Chan D.W., [The Impact of the Tumor Microenvironment on Macrophage Polarization in Cancer Metastatic Progression](https://doi.org/10.3390/ijms22126560), *International Journal of Molecular Sciences*. 2021, 22, 6560. <http://dx.doi.org/10.3390/ijms22126560> (Publication No. : 327492; Weighting : 1.0000; Publication Date: Jun 2021)

WANG J., Siu K.Y., JIANG Y., Leung T.H.Y., Chan D.W., WANG H., Ngan H.Y.S. and Chan K.K.L., [A Combination of Glutaminase Inhibitor 968 and PD-L1 Blockade Boosts the Immune Response against Ovarian Cancer](https://doi.org/10.3390/biom11121749), *Biomolecules*. 2021, 11, 1749. <http://dx.doi.org/10.3390/biom11121749> (Publication No. : 333430;

Weighting : 1.0000; Publication Date: Nov 2021)

WANG J., Siu K.Y., JIANG Y., Leung T.H.Y., Chan D.W., CHENG R., Cheung A.N.Y., Ngan H.Y.S. and Chan K.K.L., Aberrant upregulation of PDK1 in ovarian cancer cells impairs CD8⁺ T cell function and survival through elevation of PD-L1, *OncoImmunology* . <http://dx.doi.org/10.1080/2162402X.2019.1659092> (Publication No. : 305591; Weighting : 0.8889; Date Accepted for Publication: Aug 2019)

WANG M., Perucho J.A.U., Vardhanabhuti V., Ip P.C.P., Ngan H.Y.S. and Lee E.Y.P., [Radiomic Features of T2-weighted Imaging and Diffusion Kurtosis Imaging in Differentiating Clinicopathological Characteristics of Cervical Carcinoma](#), *Academic Radiology*. 2021. <http://dx.doi.org/10.1016/j.acra.2021.08.018> (Publication No. : 327440; Weighting : 0.1667; Publication Date: Sep 2021)

WANG X., Yung M.H., Sharma R., Chen F., Poon Y.T., Lam W.Y., Li B., Ngan H.Y.S., Chan K.K.L. and Chan D.W., [Epigenetic Silencing of miR-33b Promotes Peritoneal Metastases of Ovarian Cancer by Modulating the TAK1/FASN/CPT1A/NF-κB Axis](#), *Cancers*. 2021, 13, 4795. <http://dx.doi.org/10.3390/cancers13194795> (Publication No. : 333431; Weighting : 0.7000; Publication Date: Sep 2021)

Wong J.Y.H., ZHANG W., Wu Y., Choi P.H., Lo H.H.M., Wong W., Chio J.H.M., Tam H.L.C., Ngai F.W., Tarrant A.M., Wang M.P., Ngan H.Y.S. and Fong D.Y.T., [An Interactive Web-Based Sexual Health Literacy Program for Safe Sex Practice for Female Chinese University Students: Multicenter Randomized Controlled Trial](#), *Journal of Medical Internet Research*. 2021, 23, e22564. <http://dx.doi.org/10.2196/22564> (Publication No. : 322807; Weighting : 0.0769; Publication Date: Mar 2021)

XUAN Y., WANG H., Yung M.H., Chen F., Chan W.S., Chan Y.S., Tsui S.K.W., Ngan H.Y.S., Chan K.K.L. and Chan D.W., [SCD1/FADS2 fatty acid desaturases equipose lipid metabolic activity and redox-driven ferroptosis in ascites-derived ovarian cancer cells](#), *Theranostics*. 2022, 12, 3534-3552. <http://dx.doi.org/10.7150/thno.70194> (Publication No. : 333453; Weighting : 0.9000; Publication Date: Apr 2022)

Conference papers

JIANG Y., Siu K.Y., WANG J., Leung T.H.Y., Ngu S.F., Chan D.W., Cheung A.N.Y., Ngan H.Y.S. and Chan K.K.L., The upregulation of PFKFB3/PDK4 enhances ovarian cancer stemness properties in tumor progression. , The 17th Biennial Meeting of the International Gynecologic Cancer Society (IGCS 2018). (Publication No. : 290721; Weighting : 0.8889; Date Accepted for Publication: Sep 2018)

Kwong A., Shin V.Y., Chen J., Cheuk W.Y.I., Ho Y.S.C., Au C.H., Chan K.K.L., Ngan H.Y.S., Chan T.L., Ford J.M. and Ma E.S.K., Risk assessment of hereditary breast and ovarian cancer syndrome in Chinese population by multiple-gene

sequencing (Oral Presentation), Health Research Symposium 2021, Hong Kong, 23 November 2021. (Publication No. : 332780; Weighting : 0.1818; Publication Date: Nov 2021)

Ngu S.F., Tse K.Y., Chu M.Y.M., Ngan H.Y.S. and Chan K.K.L., Single-Dose Methotrexate in the Treatment of Low-Risk Gestational Trophoblastic Neoplasia – An Updated Results. , Annual Global Meeting of the International Gynecologic Cancer Society . 2021. (Publication No. : 330794; Weighting : 1.0000; Publication Date: Aug 2021)

Editorship, Invited lectures and keynote speeches

Chan K.K.L., Can ROMA replace expert ultrasound when IOTA simple rules is inconclusive, RCOG world congress 2022. (Publication No. : 334227; Weighting : 1.0000; Publication Date: Jun 2022)

Chan K.K.L., Editorial Board member, Archives of Obstetrics and Gynaecology. 2021, 2(1). (Publication No. : 333357; Weighting : 1.0000; Publication Date: Jul 2021)

Chan K.K.L., Editorial Board member, Obstetrics and Gynecology, Scientifica. 2021. (Publication No. : 333358; Weighting : 1.0000; Publication Date: Dec 2021)

Chan K.K.L., Guidelines in Management of Early Cervical Cancer, Asia-Oceania Organisation in Genital infection and neoplasia (AOGIN) Virtual Meeting. 2021. (Publication No. : 333348; Weighting : 1.0000; Publication Date: Apr 2021)

Chan K.K.L., HPV testing in Hong Kong – Where are we now, The International Federation of Cervical Pathology and Colposcopy (IFCPC) World Congress. 2021. (Publication No. : 333350; Weighting : 1.0000; Publication Date: Jun 2021)

Chan K.K.L., HPV testing in Hong Kong, Cervical Cancer Elimination Symposium on cervical cancer control in HK. 2021. (Publication No. : 333347; Weighting : 1.0000; Publication Date: Mar 2021)

Chan K.K.L., Management of low risk gestational trophoblastic disease, The 7th Biennial Meeting of Asian Society of Gynecologic Oncology. 2021. (Publication No. : 333352; Weighting : 1.0000; Publication Date: Nov 2021)

Chan K.K.L., Panelist Case Discussions, 28th International congress of the Obstetrical and Gynaecological Society of Malaysia. 2021. (Publication No. : 333351; Weighting : 1.0000; Publication Date: Jul 2021)

Chan K.K.L., Sexual dysfunction in gynaecological cancers, Sexual Medicine for Providers of Women's Health Care. 2021. (Publication No. : 333349; Weighting : 1.0000; Publication Date: May 2021)

Chan K.K.L., The use of a new biomarker, HE4, in combination with simple

ultrasound rules in the prediction of malignancy in a pelvic mass detected on ultrasound, Postgraduate Study Day, Department of Obstetrics and Gynaecology, The University of Hong Kong. 2021. (Publication No. : 333353; Weighting : 1.0000; Publication Date: Dec 2021)

Chan K.K.L., Treatment of pre-invasive cervical disease, 8th CSCCP Annual Conference. 2022. (Publication No. : 334225; Weighting : 1.0000; Publication Date: Jul 2022)

Ngan H.Y.S., Challenges in Cervical Cancer control and prevention in Hong Kong , Paving way towards Cervical Cancer Elimination Symposium on cervical cancer control in HK, March 12, 2021 [Virtual meeting]. 2021. (Publication No. : 321915; Weighting : 1.0000; Publication Date: Mar 2021)

Ngan H.Y.S., Clinical management of hereditary ovarian cancer, Advanced Workshop on Genomic Testing and Genetic Counselling for Hereditary Cancers, HKU SPACE, Hong Kong, May 15, 2021. (Publication No. : 322592; Weighting : 1.0000; Date Accepted for Publication: May 2021; Publication Date: May 2021)

Ngan H.Y.S., Editorial Board Member , Gynecologic Robotic Surgery (GRS) . 2021. (Publication No. : 321514; Weighting : 1.0000; Publication Date: Mar 2021)

Ngan H.Y.S., Editorial Board Member, Gynecology and Obstetrics Clinical Medicine (GOCM). 2021. (Publication No. : 321484; Weighting : 1.0000; Publication Date: Feb 2021)

Ngan H.Y.S., The Role of Colposcopy in the Management of Positive Cervical Cancer Screening in Referral Hospitals, Asia Oceania Research Organization on Genital Infections and Neoplasia (AOGIN) Congress 2021, April 11, 2021 [Virtual Meeting]. 2021. (Publication No. : 322234; Weighting : 1.0000; Publication Date: Apr 2021)

Ngan H.Y.S., 《医路人生——前辈说》，《妇产科规培医生医学人文教育系列活动》. (Publication No. : 333468; Weighting : 1.0000; Date Accepted for Publication: Apr 2022)

Ngu S.F., HKU-SZH SBA & EMQ Writing Workshop, 2022. (Publication No. : 333220; Weighting : 1.0000; Publication Date: May 2022)

Ngu S.F., HPV Self-Sampling for Cervical Cancer Screening, The Hong Kong College of Obstetricians and Gynaecologists Postgraduate Seminar. 2021. (Publication No. : 330796; Weighting : 1.0000; Publication Date: Nov 2021)

Ngu S.F., HPV Testing vs Cytology in Hong Kong, The Obstetrical and Gynaecological Society of Hong Kong Annual Scientific Meeting 2022. (Publication No. : 333938; Weighting : 1.0000; Publication Date: Jun 2022)

Ngu S.F., Management of Advanced Stage Endometrial Cancer, Hong Kong Sanatorium & Hospital CME in Obstetrics & Gynaecology. 2022. (Publication No. :

333937; Weighting : 1.0000; Publication Date: Jun 2022)

Ngu S.F., New Management of Low-Risk and High-Risk GTN, The 27th Asia & Oceania Federation of Obstetrics & Gynaecology (AOFOG) Hybrid Congress. 2022. (Publication No. : 333355; Weighting : 1.0000; Publication Date: May 2022)

Ngu S.F., Survivorship in Gynaecological Cancer, The Hong Kong College of Obstetricians and Gynaecologists Postgraduate Seminar. 2022. (Publication No. : 333675; Weighting : 1.0000; Publication Date: Jun 2022)

Tse K.Y., Associate editor, Cancer Medicine. 2022. (Publication No. : 332071; Weighting : 1.0000; Publication Date: Feb 2022)

Tse K.Y., COVID-19 and Gynaecological Cancer Management: Chemotherapy, Targeted Therapy, and Immunotherapy, Asia & Oceania Federation of Obstetrics & Gynaecology (AOFOG) Webinar. (Publication No. : 312291; Weighting : 1.0000; Date Accepted for Publication: Jul 2020)

Tse K.Y., Cervical Cancer in the Young, 28th International Congress of the Obstetrical and Gynaecological Society of Malaysia. 2021. (Publication No. : 332073; Weighting : 1.0000; Publication Date: Jun 2021)

Tse K.Y., Editor, Hong Kong Journal of Gynaecology Obstetrics & Midwifery. 2021. (Publication No. : 332070; Weighting : 1.0000; Publication Date: Jul 2021)

Tse K.Y., Fertility Issues and its Preservation in Gynecologic Cancers, International Gynecologic Cancer Society (IGCS) - Nepal Project ECHO. 2021. (Publication No. : 332074; Weighting : 1.0000; Publication Date: Jan 2021)

Tse K.Y., Guest Editor, Frontiers in Oncology. (Publication No. : 312288; Weighting : 1.0000; Date Accepted for Publication: Dec 2020)

Tse K.Y., Guest Editor, Frontiers in Oncology. (Publication No. : 312287; Weighting : 1.0000; Date Accepted for Publication: Dec 2020)

Tse K.Y., Robotic vs open surgery for uterine cancer, Asian Society for Gynecological Robotic Surgery 2021. (Publication No. : 332072; Weighting : 1.0000; Publication Date: Nov 2021)

Tse K.Y., Subspecialty training in gynecological cancer, The 3rd HKU-SZH Gynaecological Oncology Symposium. 2021. (Publication No. : 332075; Weighting : 1.0000; Publication Date: Dec 2021)

